Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11006983 | 0.86 | TACR1 (0.57) | TACR1P2RX1CES2MAPT | |
| SCHEMBL12435510 | 0.82 | TACR1 (0.54) | TACR1P2RX1CES2MLYCDMAPT | |
| SCHEMBL15397669 | 0.77 | TACR1 (0.59) | TACR1P2RX1CES2MAPT | |
| SCHEMBL12435579 | 0.77 | MLYCD (0.57) | TACR1P2RX1CES2HDAC8S1PR1 | |
| SCHEMBL11406952 | 0.76 | TACR1 (0.60) | TACR1P2RX1CES2 | |
| SCHEMBL12587317 | 0.74 | MLYCD (0.44) | TACR1P2RX1CES2HDAC8S1PR1 | |
| SCHEMBL12436257 | 0.73 | TACR1 (0.46) | TACR1P2RX1CES2MLYCDMAPT | |
| SCHEMBL9823718 | 0.73 | TACR1 (0.57) | TACR1P2RX1CES2MAPT | |
| SCHEMBL5788964 | 0.72 | TACR1 (0.63) | TACR1P2RX1CES2HDAC8S1PR1 | |
| SCHEMBL12513373 | 0.72 | TACR1 (0.51) | TACR1P2RX1CES2HDAC8MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | TACR1 13/4885P2RX1 1137/4885CES2 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.